Nearly half of working-age adults were inadequately insured in 2026, and half went without needed care due to cost, a Commonwealth Fund survey found.
News|Articles|March 25, 2026
Promise, Pitfalls, and Progress of Price Transparency in US Health Care: John Barkett
Author(s)Pearl Steinzor
Fact checked by: Julia Bonavitacola
Making health care prices public was supposed to cut costs. The reality is more complicated.
Advertisement
Advertisement
Price transparency was sold as one of health care’s simple fixes. The aim was to show patients and employers what insurers actually pay for their care, allowing market forces to do the rest.
Related to this article
AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.
As CKCC nears its sunset, kidney care leaders urge CMS to preserve a dedicated, nephrologist-led accountable care model for advanced kidney disease.
Speakers at ASN Kidney Week urge nephrologists to appeal prior authorization denials, include children in trials, and expand access to glomerular disease therapies globally.
Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.
Medicare’s GLP-1 Bridge program aims to expand obesity treatment, but eligibility hurdles and drug costs leave many seniors paying hundreds monthly.
At IDWeek 2026, Atul Gawande, MD, MPH, said USAID cuts are costing lives but that the field is "not back at square one."
More treatment choices does not always mean better patient outcomes, with care access remaining challenging in Florida.
Advertisement
Advertisement